Drugs / GLP-1 (7-36) amide
GLP-1 (7-36) amide
also known as
GLP-1 · Glucagon-like peptide-1 (7-36) amide · MKC253 · AC2592 · Glucagon-like peptide-1 · Human GLP-1 (7-36) amide
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02128022 | Jul 2014 → Mar 2016 | coronary artery disorder | Papworth Hospital NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT00642538 | Feb → Sep 2008 | type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00475371 | Apr → Jun 2007 | type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00099580 | Mar 2005 → Sep 2006 | congestive heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03502083 | Dec 2015 → Mar 2017 | coronary stenosis, intermediate coronary syndrome, type 2 diabetes mellitus | Papworth Hospital NHS Foundation Trust | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT00882492 Comparator | Dec 2008 → May 2011 | hyperglycemia, hypoglycemia | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00966654 Comparator | Sep 2008 → Aug 2009 | — | Johns Hopkins University | Terminated | No outcome recorded |
| — | NCT01333163 Comparator | May → Dec 2011 | — | Jeppe Skov | Completed | No outcome recorded |
| — | NCT00285896 Comparator | Dec 2005 → Oct 2006 | type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-30 | Mannkind Corporation | Results MannKind Corporation Response to Recent Market Events mannkindcorp.com ↗
Following administration of MKC253, study subjects experienced a dose-dependent increase in insulin levels and a decrease in glucose levels. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Mannkind Corporation | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management mannkindcorp.com ↗ |
| 2026-06-08 | AstraZeneca | Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio astrazeneca.com ↗ |
| 2017-10-30 | Mannkind Corporation | MannKind Corporation Response to Recent Market Events mannkindcorp.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLP-1(7-36 amide) | “GLP-1(7-36 amide) or placebo was continuously infused subcutaneously and titrated to a dose of 4.8 pmol/kg per min.” PMID 19094067 ↗ Dec 20084“This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)” NCT00882492 ↗ |
| Known as | AC2592 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00099580 ↗ |
| Known as | GLP-1 | “Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans.” PMID 27431258 ↗ Jul 20161“Glucagon-like peptide-1 (GLP-1) is an incretin hormone with multiple actions in addition to control of glucose homeostasis.” PMID 23463656 ↗ Mar 2013 |
| Known as | Glucagon-like peptide-1 | “Glucagon-like peptide-1 (GLP-1) is an incretin hormone with multiple actions in addition to control of glucose homeostasis.” PMID 23463656 ↗ Mar 2013 |
| Known as | Glucagon-like peptide-1 (7-36) amide | “Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans.” PMID 27431258 ↗ Jul 2016 |
| Known as | Human GLP-1 (7-36) amide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01333163 ↗ |
| Known as | MKC253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00475371 ↗ |
| Modality | Peptide | “1.5 mg dose of GLP-1 as MKC253 Inhalation Powder” NCT00642538 ↗ |
| Route | Subcutaneous | “continuous subcutaneous infusion (via pump), dose based on subject body weight” NCT00099580 ↗ |